Nye behandlinger af Graves' sygdom med fokus på det B-lymfocyt-depleterende antistof rituximab

TY - JOUR

T1 - Nye behandlinger af Graves' sygdom med fokus på det B-lymfocyt-depleterende antistof rituximab

AU - Nielsen, Claus Henrik

AU - El Fassi, Daniel

AU - Hegedüs, Laszlo

PY - 2008/6/9

Y1 - 2008/6/9

N2 - Graves' disease (GD) is caused by autoantibodies to the thyrotropin receptor (TRAb). In a controlled study using the B-lymphocyte depleting agent rituximab (RTX), an RTX-specific effect was found on long-term remission following methimazole (MMI) therapy. However, benefits were limited to patients with low baseline TRAb levels, and the decrease in TRAb levels observed after treatment with RTX in combination with MMI was no greater than that observed after treatment with MMI alone. Considering its price and adverse effect profile, RTX therapy does not seem to be a relevant treatment option in uncomplicated GD. The potential use of other immunomodulatory agents in GD is discussed.

AB - Graves' disease (GD) is caused by autoantibodies to the thyrotropin receptor (TRAb). In a controlled study using the B-lymphocyte depleting agent rituximab (RTX), an RTX-specific effect was found on long-term remission following methimazole (MMI) therapy. However, benefits were limited to patients with low baseline TRAb levels, and the decrease in TRAb levels observed after treatment with RTX in combination with MMI was no greater than that observed after treatment with MMI alone. Considering its price and adverse effect profile, RTX therapy does not seem to be a relevant treatment option in uncomplicated GD. The potential use of other immunomodulatory agents in GD is discussed.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 170

SP - 2131

EP - 2134

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 24

ER -